Evaluation of the Role of Claudin-۴ Antigen Overexpression in Triple-Negative Breast Cancer Patients: A ۵-Year Survival Analysis
- سال انتشار: 1404
- محل انتشار: فصلنامه آسیب شناسی ایران، دوره: 20، شماره: 2
- کد COI اختصاصی: JR_IJP-20-2_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 66
نویسندگان
Department of Pathology, Reproductive Sciences and Sexual Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Pathology, Reproductive Sciences and Sexual Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
School of Health, Department of Biostatistics and Epidemiology, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده
Background & Objective: Breast cancer (BC) can be categorized into ۴ groups based on molecular and pathological evidence: Luminal A, Luminal B, HER۲+ tumors, and triple-negative breast cancer (TNBC). TNBC has a poorer survival rate and a higher chance of recurrence and metastasis compared to other BC types, primarily due to its challenging treatment course. Claudin ۴ (CLDN۴), a transmembrane protein in tight junctions between cells, has been linked to poor prognosis and faster disease progression in these malignancies.Methods: Patients previously diagnosed with TNBC and tested for CLDN۴ overexpression were contacted for follow-up and to determine disease outcomes. The current health status, cause, and time of death (if applicable) were recorded. Patient files were accessed to obtain information on age, tumor size and grading, lymph node involvement, metastasis, Ki۶۷, and CLDN۴ expression.Results: Patients with high CLDN expression showed a significantly lower mortality rate. However, after controlling for other covariates, the hazard ratio (HR) was ۰.۴۸ (۹۵%CI= [۰.۱۳ – ۱.۲۷]) in the crude model for survival, ۰.۵۴ (۹۵%CI = [۰.۲ – ۱.۴۳]) when adjusted for age at diagnosis, and ۰.۵۸ (۹۵%CI = [۰.۱۸-۱.۸۲]) when adjusted for other covariates. CLDN۴ was also not correlated with tumor metastasis (HR=۰.۶۴, p=۰.۲۰۳, in the crude model; HR=۰.۵۲, p=۰.۴۰۹, when adjusted for other covariates). Patients in the CLDN۴ high group had a significantly higher number of tumors > ۲cm.Conclusion: Although previous studies have shown that CLDN۴ overexpression worsens TNBC prognosis and increases metastasis or recurrence, the current study found no such association.کلیدواژه ها
Breast neoplasms, Claudin-۴, Biomarkers, Prognosis, Neoplasm Metastasisاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.